0 Replies
Download PDF
miRagen licenses rights to utilize Santaris Pharma A/S proprietary Locked Nucleic Acid (LNA) Drug Platform to identify and select drug candidates against miRagen’s proprietary microRNA targets for the treatment of cardiovascular disease
Santaris Pharma A/S obtains a minority equity interest in miRagen in addition to milestone payments and... Contine Reading & Discuss→
0 Replies
Hoersholm, Denmark/San Diego, California & Boulder, Colorado, June 23, 2010 — Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies and miRagen Therapeutics, Inc., a biopharmaceutical company focused on developing innovative microRNA-based therapeutics for cardiovascular and muscle disease, announced today that they have... Contine Reading & Discuss→
0 Replies
Stories include:
Regulus Pharmaceuticals is partnering up with Sanofi-Aventis in a $750 million microRNA discovery and development deal, garnering $25 million of that upfront with the promise of a $10 million equity payment. Launched with the backing of Alnylam and Isis, Regulus also obtained an option on a broader R&D... Contine Reading & Discuss→
0 Replies
Stories include:
Igenica, a cancer antibody start-up based in Burlingame, CA, is reporting that it raised $24 million in a Series B. The new round was led by The Column Group, OrbiMed Advisors and 5AM Ventures.
Launched a little more than a year ago, Igenica says it uses two technology... Contine Reading & Discuss→
0 Replies
WORCESTER, Mass., Jun 10, 2010 (BUSINESS WIRE) –RXi Pharmaceuticals Corporation (Nasdaq: RXII), a recognized leader in RNAi-based therapeutic discovery and development, today announced the company’s new focused RNAi therapeutic strategy at the Jefferies 2010 Global Life Sciences Conference. Contine Reading & Discuss→
0 Replies
Stories include:
CNET reviews Pantec's new Painless Laser Epidermal System, which uses lasers to create micropores in the skin, doing away with injections. Medical professionals can adjust the delivery device for diabetics to use at home, and there's a desktop unit that can be used in the clinic for faster... Contine Reading & Discuss→
0 Replies
EINDHOVEN, Netherlands & WORCESTER, Mass., Jun 03, 2010 (BUSINESS WIRE) –Royal Philips Electronics (NYSE: PHG, AEX: PHI) andRXi Pharmaceuticals Corporation (Nasdaq: RXII), a US-based biopharmaceutical company, today announced that they have entered into a joint research agreement to explore the benefits of combining proprietary technologies from both companies for the... Contine Reading & Discuss→
0 Replies
WORCESTER, Mass., Jun 02, 2010 (BUSINESS WIRE) –RXi Pharmaceuticals Corporation (Nasdaq: RXII), a recognized leader in RNAi-based therapeutic discovery and development, today announced that the Company’s President and Chief Executive Officer, Noah D. Beerman, will present a corporate overview at the Jefferies 2010 Global Life Sciences Conference on Thursday, June... Contine Reading & Discuss→
